{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:01:18Z","timestamp":1758142878250,"version":"3.44.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"J. Arch McNamara, MD Fund for Retina Research and Education, Philadelphia, PA"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To study the natural history and anatomical characteristics of geographic atrophy in eyes with dry age-related macular degeneration (dAMD) compared with fellow eyes with macular atrophy and concurrent neovascular AMD (nAMD) treated with anti-vascular endothelial growth factor injections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a single-center, retrospective chart review. Data were recorded at two time points (#1 and #2) one year apart. Two independent graders reviewed the images to measure atrophy area and grade it based on the Consensus on Atrophy Meeting group criteria. Difference in atrophy area between the two time points was calculated. A square root transformation was also performed to report the change in atrophy progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two hundred eight eyes of 104 patients were included: 104 eyes had dAMD and 104 fellow eyes had nAMD. The mean (SD) atrophy area was 14.05 (9.96) mm<jats:sup>2<\/jats:sup> in dAMD eyes and 14.14 (9.26) mm<jats:sup>2<\/jats:sup> in nAMD eyes (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.95) at time point #1, and 16.92 (10.83) mm<jats:sup>2<\/jats:sup> in dAMD eyes and 17.35 (11.03) mm<jats:sup>2<\/jats:sup> in nAMD eyes (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.78) at time point #2. The mean (SD) atrophy growth rate was 3.08 (2.52) mm<jats:sup>2<\/jats:sup>\/year in the nAMD eyes and 2.77 (1.88) mm<jats:sup>2<\/jats:sup>\/year in the dAMD eyes (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.32). Using the square root transformation, the growth rates were 0.40 (0.24) mm\/year in nAMD and 0.38 (0.22) mm\/year in dAMD (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.55).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Geographic atrophy in eyes with dAMD and macular atrophy in fellow eyes with nAMD exhibit similar growth rates, suggesting a high degree of concordance and potentially a similar mechanism of atrophy development and progression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004567","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T16:00:10Z","timestamp":1751040010000},"page":"1833-1841","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["ATROPHY GROWTH RATES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION COMPARED WITH FELLOW EYES WITH DRY AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-4219","authenticated-orcid":false,"given":"Jason","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cappellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-7369","authenticated-orcid":false,"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay E.","family":"Kuriyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250917","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"R2-20250917","doi-asserted-by":"crossref","first-page":"100306","DOI":"10.1016\/j.xops.2023.100306","article-title":"Geographic atrophy in age-related macular degeneration: a tale of two stages","volume":"3","author":"Keenan","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"R3-20250917","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"R4-20250917","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajo.2022.06.023","article-title":"Comparison of fundus autofluorescence versus optical coherence tomography-based evaluation of the therapeutic response to pegcetacoplan in geographic atrophy","volume":"244","author":"Mai","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R5-20250917","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.oret.2018.04.009","article-title":"Atrophy in neovascular age-related macular degeneration: age-related eye disease study 2 report number 15","volume":"2","author":"Domalpally","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R6-20250917","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"key":"R7-20250917","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.oret.2017.01.004","article-title":"Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration: VIEW 1 extension study","volume":"1","author":"Kaiser","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"R8-20250917","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 Years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"R9-20250917","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ophtha.2020.03.031","article-title":"Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR study for neovascular age-related macular degeneration","volume":"127","author":"Sadda","year":"2020","journal-title":"Ophthalmology"},{"key":"R10-20250917","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","article-title":"Fellow eye comparisons for 7-year outcomes in ranibizumab- treated AMD subjects from anchor, marina, and horizon (seven-up study)","volume":"123","author":"Bhisitkul","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20250917","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajo.2020.01.005","article-title":"Near-infrared reflectance imaging for quantification of atrophy associated with age-related macular degeneration","volume":"212","author":"Abdelfattah","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R12-20250917","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2006.09.016","article-title":"The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials","volume":"114","author":"Sunness","year":"2007","journal-title":"Ophthalmology"},{"key":"R13-20250917","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"R14-20250917","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2010.08.018","article-title":"Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography","volume":"118","author":"Yehoshua","year":"2011","journal-title":"Ophthalmology"},{"key":"R15-20250917","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2006.11.041","article-title":"Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration","volume":"143","author":"Holz","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R16-20250917","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"key":"R17-20250917","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2019.09.030","article-title":"Spectral-domain OCT-based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"127","author":"Gune","year":"2020","journal-title":"Ophthalmology"},{"key":"R18-20250917","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1007\/s00417-023-06168-0","article-title":"Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes","volume":"261","author":"Blazaki","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R19-20250917","first-page":"3504","article-title":"Geographic atrophy in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF compared to untreated fellow eyes without nAMD","volume":"61","author":"Grobben","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20250917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol Assess"},{"key":"R21-20250917","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ophtha.2014.07.046","article-title":"Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration","volume":"122","author":"Tanaka","year":"2015","journal-title":"Ophthalmology"},{"key":"R22-20250917","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ophtha.2019.11.016","article-title":"Incidence of macular atrophy after untreated neovascular age-related macular degeneration: age-related eye disease study report 40","volume":"127","author":"Christakis","year":"2020","journal-title":"Ophthalmology"},{"key":"R24-20250917","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.oret.2022.04.012","article-title":"Differences in long-term progression of atrophy between neovascular and nonneovascular age-related macular degeneration","volume":"6","author":"Airaldi","year":"2022","journal-title":"Ophthalmol Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:01:18Z","timestamp":1758121278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004567","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}